Navigation Links
Haemonetics Expands Its Blood Management Product Portfolio with Acquisition of SEBRA Business Unit
Date:9/8/2009

BRAINTREE, Mass. and TUCSON, Ariz., Sept. 8 /PRNewswire-FirstCall/ -- Haemonetics Corporation, a global blood management solutions company, and Engineering and Research Associates Inc. (known as "SEBRA(R)"), a leading provider of blood and medical manufacturing technologies, announced today that Haemonetics has acquired the assets of SEBRA's blood collection and processing business for $12.5 million cash. The acquisition is expected to close within the next several weeks.

Haemonetics helps hospitals and blood collectors to improve patient care and lower costs by optimizing the collection, processing, and use of scarce blood resources. The Company's broad product offering includes blood collection and separation technologies, surgical blood salvage systems, information technology platforms, and consulting services that better manage the blood supply chain through improved blood management practices.

Through its Biological Collection and Processing Division, SEBRA markets a suite of products used in blood collection and processing which can improve quality and regulatory compliance of blood products. The Division's principal products include:

  • Radio-Frequency (RF) Tube sealers -- Tubing sealers are used to seal and segment parts of the consumables used in blood collection, while maintaining a sterile environment for the collected blood. Sterility is critical in ensuring the highest quality blood component for transfusion.
  • Whole Blood Collection Devices (Shakers) -- Shaker devices rock blood units throughout the donation to facilitate proper mixing of an anticoagulant, included in the blood bag, and the donated blood. Proper mixing of anticoagulant and blood ensures that the red cells won't clot. (Red cell clotting during filtration is a major reason for blood discards.) SEBRA's shaker devices also weigh blood units during collection to ensure that the right amount of blood is consistently collected from donors.
  • Mobile Collection & Ancillary Equipment -- Mobile lounges, tourniquets, temperature stabilizers, supply cases, and more are utilized on mobile drives. Blood collection is analogous to a manufacturing line that gets moved every day. SEBRA's products are designed with the robustness and portability to support the rigors of a mobile drive.

Brian Concannon, Haemonetics' President and CEO, said, "Haemonetics is well established as the global leader in blood management solutions, and the SEBRA products further expand the breadth of our product offering. As importantly, these products strengthen Haemonetics' footprint in the whole blood collection market in advance of our launch of an automated whole blood collection system which is currently in development." Haemonetics' automated whole blood collection system will combine an automated whole blood collection device with integrated information technology for donor and process management, and a blood transport system that standardizes the blood storage and transport process, thereby strengthening regulatory and quality compliance efforts. Haemonetics expects to launch the automated whole blood collection system in late fiscal 2011.

Roger Vogel, President and CEO of Engineering and Research Associates, said, "Our blood collection products address an important and growing market. The sale of the business line to Haemonetics ensures a great strategic partner which can further grow the business through its global marketing reach. Additionally, Haemonetics' broad presence in the plasma collection market can facilitate expansion of the SEBRA products into the plasma collection centers. For Engineering and Research Associates, the sale will enable further worldwide expansion of its industry leading Medical Manufacturing Technology products and solutions, which provide engineering consulting services and new technologies for thermal-forming, sealing and welding plastics for medical device manufacturing and biopharmaceutical companies in more than 60 countries."

Based in Tucson, Arizona, Engineering and Research Associates will remain a global company dedicated to the development of innovative technology and quality products for the medical device manufacturing and biopharmaceutical industries. The company will operate under a new company name to be announced later this year. Haemonetics will retain the SEBRA brand and will relocate the SEBRA Blood Collection and Processing Division to its Braintree and Salt Lake City locations.

The SEBRA Blood Collection and Processing business had $10 million in sales in 2008 and has a 10 year compounded annual growth rate for revenues of more than 9%. The acquisition is expected to be neutral to earnings per share in fiscal 2010 and accretive in fiscal 2011.

Haemonetics and Engineering and Research Associates have posted frequently asked questions on Haemonetics' website at http://www.haemonetics.com/site/content/km/factSheet.asp.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site athttp://www.haemonetics.com.

This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.

    CONTACT:
    Julie Fallon
    Tel. (781) 356-9517
    Alternate Tel. (617) 320-2401
    fallon@haemonetics.com


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release: August 3, 2009
2. Haemonetics Shares Success of Outstanding Fiscal 2009 Performance with Employees
3. Haemonetics Sets Date For Fourth Quarter Fiscal Year 2009 Earnings Release: May 4, 2009
4. Haemonetics Sets Date for Investor/Analyst Meeting
5. Haemonetics Expands Its Blood Management Leadership With Acquisition of Neoteric Technology Ltd
6. Haemonetics Announces Change to Board of Directors
7. Haemonetics Bolsters Blood Bank Information Management Portfolio With Acquisition of Altivation Software
8. Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
9. Haemonetics to Present at J.P. Morgan Healthcare Conference
10. Dr. Jonathan White Joins Haemonetics as Head of Research and Development
11. Haemonetics Announces Promotion of Brian Concannon to CEO Effective April 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Discover the Rocky ... over 1,400 booths and 700 companies. Attendees also get to see the most ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 14th ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... , ... Shark Finds and Kevin Harrington, along with the Product ... with Belly Bands. , Having a dog is great—except when it wets every couch, ... nothing works, get Belly Bands, the easiest way to stop dogs from wetting ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... --> ... Market Research titled, "World Synthetic Biology ... the world synthetic biology market to be $5.2 ... segment would continue to lead the market until ... held around half of the market share in ...
(Date:2/5/2016)... ANGELES , Feb. 5, 2016  Redwood Scientific ... a new product designed to help women balance their ... strip delivery technology. Jason Cardiff , ... will be able to help the millions of women ... from the effects of imbalanced hormones. Our research and ...
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
Breaking Medicine Technology: